A new type of drug-treated cigarettes aimed at low-ering bronchopulmonary lesions have been studied. Therats smoking ordinary cigarettes were compared with therats smoking cigarettes treated with Chinese traditionaldr...A new type of drug-treated cigarettes aimed at low-ering bronchopulmonary lesions have been studied. Therats smoking ordinary cigarettes were compared with therats smoking cigarettes treated with Chinese traditionaldrugs which possessed anti-inflammatory and detoxicationeffects. The results showed that bronchiolar and bronchi-olopulmonary lesions are less in the drug-treated groupby histopathologic observation. We also found that bacte-riophagocytosis and immunocytochemical lysozyme reac-tions of alveolar macrophages in bronchial alveolar lavagefluids from the drug-treated cigarette smoking rats wereweakened. There are some differences of surface ultra-structures of alveolar macrophages between the ordinarysmoking group and the drug-treated smoking group. Thisindicated differentially functional states of these alveo-lar macrophages in the different groups.展开更多
This study aimed to evaluate emerging trends of drug resistance to nucleoside reverse transcriptase inhibitors (NRTIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs) among 290 former blood donor HIV-1 inf...This study aimed to evaluate emerging trends of drug resistance to nucleoside reverse transcriptase inhibitors (NRTIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs) among 290 former blood donor HIV-1 infected patients in Hubei, China, from 2004 to 2006, all of whom had received anti-HIV-1 therapy. The presence of NRTI- and NNRTI-associated mutations were established by sequencing; genotypic and predicted phenotypic drug resistance were evaluated using HIVdb Program version 5.0.1 (http://hivdb.stanford.edu/ pages/algs/HIVdb.html). Genotypic drug resistance analysis showed significant increases in percentages of patients carrying HIV-1 strains with M41L, T215Y/F, D67N, K103N, G190A/S, Y181C/F or L210W mutations. Of the variants' predicted phenotypic drug resistance, highly significant increases were detected in percentages of patients carrying HIV-1 with high resistance to zidovudine (AZT) or stavudine (D4T) in NRTIs, and to delavirdine (DLV), efavirenz (EFV) or nevirapine (NVP) in NNRTIs; intermediate resistance to abacavir (ABC), AZT, D4T, didanosine (DDI) or tenofovir disoproxil fumarate (TDF) in NRTIs, and to etravirine (ETR) in NNRTIs; and low and potential low resistance to lamivudine (3TC), ABC, emtricitabine (FTC) or TDF in NRTIs, and to ETR in NNRTIs.展开更多
文摘A new type of drug-treated cigarettes aimed at low-ering bronchopulmonary lesions have been studied. Therats smoking ordinary cigarettes were compared with therats smoking cigarettes treated with Chinese traditionaldrugs which possessed anti-inflammatory and detoxicationeffects. The results showed that bronchiolar and bronchi-olopulmonary lesions are less in the drug-treated groupby histopathologic observation. We also found that bacte-riophagocytosis and immunocytochemical lysozyme reac-tions of alveolar macrophages in bronchial alveolar lavagefluids from the drug-treated cigarette smoking rats wereweakened. There are some differences of surface ultra-structures of alveolar macrophages between the ordinarysmoking group and the drug-treated smoking group. Thisindicated differentially functional states of these alveo-lar macrophages in the different groups.
基金The Key Projects in the National Science & Technology Pillar Program during the Eleventh Five-Year Plan Period of China (2008ZX10001-002)the Major Science and Technology Innovation Cross Project of the Chinese Academy of Sciences (KSCX1-YW-10)
文摘This study aimed to evaluate emerging trends of drug resistance to nucleoside reverse transcriptase inhibitors (NRTIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs) among 290 former blood donor HIV-1 infected patients in Hubei, China, from 2004 to 2006, all of whom had received anti-HIV-1 therapy. The presence of NRTI- and NNRTI-associated mutations were established by sequencing; genotypic and predicted phenotypic drug resistance were evaluated using HIVdb Program version 5.0.1 (http://hivdb.stanford.edu/ pages/algs/HIVdb.html). Genotypic drug resistance analysis showed significant increases in percentages of patients carrying HIV-1 strains with M41L, T215Y/F, D67N, K103N, G190A/S, Y181C/F or L210W mutations. Of the variants' predicted phenotypic drug resistance, highly significant increases were detected in percentages of patients carrying HIV-1 with high resistance to zidovudine (AZT) or stavudine (D4T) in NRTIs, and to delavirdine (DLV), efavirenz (EFV) or nevirapine (NVP) in NNRTIs; intermediate resistance to abacavir (ABC), AZT, D4T, didanosine (DDI) or tenofovir disoproxil fumarate (TDF) in NRTIs, and to etravirine (ETR) in NNRTIs; and low and potential low resistance to lamivudine (3TC), ABC, emtricitabine (FTC) or TDF in NRTIs, and to ETR in NNRTIs.
